Published in AIDS on September 12, 2008
A Comparison of Two Ways to Manage Anti-HIV Treatment (The SMART Study) | NCT00027352
Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis (2010) 5.35
Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr (2011) 2.21
Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology (2010) 2.17
Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis (2014) 2.16
Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials. HIV Clin Trials (2010) 1.75
Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. J Acquir Immune Defic Syndr (2010) 1.70
Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS (2009) 1.67
Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS (2011) 1.57
Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review. PLoS One (2013) 1.49
Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study. AIDS (2010) 1.46
Kidney function and the risk of cardiovascular events in HIV-1-infected patients. AIDS (2010) 1.37
Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. AIDS (2012) 1.34
No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis (2011) 1.32
Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study. BMC Infect Dis (2012) 1.26
Highly sensitive C-reactive protein, body mass index, and serum lipids in HIV-infected persons receiving antiretroviral therapy: a longitudinal study. J Acquir Immune Defic Syndr (2009) 1.16
Markers of atherosclerosis and inflammation and mortality in patients with HIV infection. Atherosclerosis (2010) 1.05
Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals. AIDS Res Hum Retroviruses (2010) 1.04
Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir. BMC Infect Dis (2011) 1.03
Markers of inflammation and coagulation indicate a prothrombotic state in HIV-infected patients with long-term use of antiretroviral therapy with or without abacavir. AIDS Res Ther (2010) 1.03
Long-term predictive value of the Framingham Risk Score for Stroke in HIV-positive vs HIV-negative men. Neurology (2013) 1.00
SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen. Clin Infect Dis (2013) 0.99
The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: shifting paradigms. Curr Opin HIV AIDS (2009) 0.96
Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution. Int J Vasc Med (2011) 0.95
Initiation of antiretroviral therapy at high CD4 cell counts: does it reduce the risk of cardiovascular disease? Curr Opin HIV AIDS (2014) 0.94
Management of HIV infection in treatment-naive patients: a review of the most current recommendations. Am J Health Syst Pharm (2011) 0.91
Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase. AIDS (2011) 0.91
Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study. Antivir Ther (2013) 0.91
Inflammatory Markers Associated with Coronary Heart Disease in Persons with HIV Infection. Curr Infect Dis Rep (2011) 0.90
Relationship of body composition, metabolic status, antiretroviral use, and HIV disease factors to endothelial dysfunction in HIV-infected subjects. AIDS Res Hum Retroviruses (2010) 0.89
Soluble CD163 does not predict first-time myocardial infarction in patients infected with human immunodeficiency virus: a nested case-control study. BMC Infect Dis (2013) 0.89
Increased prevalence of albuminuria in HIV-infected adults with diabetes. PLoS One (2011) 0.89
Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES. AIDS Res Hum Retroviruses (2012) 0.88
Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy. BMC Infect Dis (2011) 0.88
Biomarkers and HIV-associated cardiovascular disease. Curr Opin HIV AIDS (2010) 0.87
Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration. BMC Med (2016) 0.86
Management of dyslipidemia in HIV-infected patients. Clin Lipidol (2011) 0.83
A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individuals. PLoS One (2015) 0.83
Efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV infected children and adolescents: a systematic review and meta-analysis. BMC Infect Dis (2015) 0.83
Cardiac risk: not so simple. J Infect Dis (2010) 0.82
Pathophysiology and management of cardiovascular disease in patients with HIV. Lancet Diabetes Endocrinol (2016) 0.82
HIV infection induces structural and functional changes in high density lipoproteins. Atherosclerosis (2015) 0.82
Current Efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia. PLoS One (2015) 0.81
Nucleoside reverse transcriptase inhibitors in combination therapy for HIV patients: systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis (2010) 0.81
Effects of combination antiretroviral therapies on the risk of myocardial infarction among HIV patients. Epidemiology (2014) 0.81
Nutritional and metabolic correlates of cardiovascular and bone disease in HIV-infected patients. Am J Clin Nutr (2011) 0.81
Short communication: initiation of an abacavir-containing regimen in HIV-infected adults is associated with a smaller decrease in inflammation and endothelial activation markers compared to non-abacavir-containing regimens. AIDS Res Hum Retroviruses (2012) 0.81
Antiretroviral therapy for adults infected with HIV: Guidelines for health care professionals from the Quebec HIV care committee. Can J Infect Dis Med Microbiol (2011) 0.80
Diabetes and Hypertension among Patients Receiving Antiretroviral Treatment Since 1998 in Senegal: Prevalence and Associated Factors. ISRN AIDS (2012) 0.80
Switching antiretroviral therapy to minimize metabolic complications. HIV Ther (2010) 0.80
Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV. Adv Ther (2010) 0.80
Abacavir/lamivudine combination in the treatment of HIV: a review. Ther Clin Risk Manag (2010) 0.79
Vitamin D insufficiency and subclinical atherosclerosis in non-diabetic males living with HIV. J Int AIDS Soc (2014) 0.79
Abacavir alters the transcription of inflammatory cytokines in virologically suppressed, HIV-infected women. J Int AIDS Soc (2012) 0.79
Sex differences in urinary biomarkers of vascular and endothelial function in HIV-infected persons receiving antiretroviral therapy. Antivir Ther (2011) 0.79
Adverse outcome analyses of observational data: assessing cardiovascular risk in HIV disease. Clin Infect Dis (2011) 0.79
Acute coronary syndrome in HIV patients: from pathophysiology to clinical practice. Cardiovasc Diagn Ther (2012) 0.79
Epidemiology and management of antiretroviral-associated cardiovascular disease. Open AIDS J (2015) 0.78
A review of cardiovascular and renal function monitoring: a consideration of older adults with HIV. HIV AIDS (Auckl) (2013) 0.78
HIV Infection, Antiretroviral Therapy and Cardiovascular Risk. Mediterr J Hematol Infect Dis (2010) 0.78
Cardiovascular Complications of HIV-Associated Immune Dysfunction. Cardiol Res Pract (2015) 0.78
What's new for antiretroviral treatment in women with HIV. J Virus Erad (2016) 0.78
Antiviral efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV-infected children and adolescents: a systematic review protocol. Syst Rev (2014) 0.77
Brachial and central blood pressure in HIV-infected subjects. Hypertens Res (2015) 0.77
HIV-induced immune activation: pathogenesis and clinical relevance - summary of a workshop organized by the German AIDS Society (DAIG e.v.) and the ICH Hamburg, Hamburg, Germany, November 22, 2008. Eur J Med Res (2010) 0.76
Recent key advances in human immunodeficiency virus medicine and implications for China. AIDS Res Ther (2010) 0.76
Effectiveness and safety of generic version of abacavir/lamivudine and efavirenz in treatment naïve HIV-infected patients: a nonrandomized, open-label, phase IV study in Cali-Colombia, 2011-2012. BMC Infect Dis (2016) 0.75
Challenges in initiating antiretroviral therapy in 2010. Can J Infect Dis Med Microbiol (2010) 0.75
Decline in CD4 T lymphocytes with monotherapy bridging strategy for non-adherent adolescents living with HIV infection: Results of the IMPAACT P1094 randomized trial. PLoS One (2017) 0.75
Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine. PLoS One (2011) 0.75
Cardiovascular, renal and liver events associated with human immunodeficiency virus type 1 infection and antiretroviral therapy. F1000 Med Rep (2009) 0.75
Combination dolutegravir-abacavir-lamivudine in the management of HIV/AIDS: clinical utility and patient considerations. Patient Prefer Adherence (2015) 0.75
Antiretroviral therapy: when to start. Infect Dis Clin North Am (2014) 0.75
Practical Considerations For Developing Nucleoside Reverse Transcriptase Inhibitors. Drug Discov Today Technol (2012) 0.75
PharmGKB summary: abacavir pathway. Pharmacogenet Genomics (2014) 0.75
Noninvasive coronary imaging for atherosclerosis in human immunodeficiency virus infection. Curr Probl Diagn Radiol (2011) 0.75
Prevalence and risk factors of low bone mineral density in Korean HIV-infected patients: impact of abacavir and zidovudine. J Korean Med Sci (2013) 0.75
Novel approaches to HIV therapy. F1000Res (2017) 0.75
A Review of Management of Inflammation in the HIV Population. Biomed Res Int (2016) 0.75
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients. PLoS One (2017) 0.75
Should abacavir be a first-line alternative for adults with HIV in sub-Saharan Africa? J Acquir Immune Defic Syndr (2017) 0.75
Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med (2005) 28.21
CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med (2006) 22.76
Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med (2007) 12.93
Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med (2003) 12.23
Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab (2007) 9.77
HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med (2008) 9.75
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet (2008) 8.73
Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr (2003) 4.64
Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med (2008) 4.34
Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther (2008) 2.93
Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis (2007) 2.69
Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J (2000) 1.83
Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Med (2005) 1.49
Major coronary risk factors and death from coronary heart disease: baseline and follow-up mortality data from the Second National Health and Nutrition Examination Survey (NHANES II). Am J Prev Med (2005) 1.37
Platelet activation induced by interleukin-6: evidence for a mechanism involving arachidonic acid metabolism. Thromb Haemost (1994) 1.09
Asymptomatic myocardial ischaemia in HIV-infected adults. AIDS (2008) 1.00